The encouraging result comes just days after the US FDA approved Vertex Pharma's non-opioid painkiller Journavx (suzetrigine) ...

Düsseldorf, Germany Wednesday, February 5, 2025, 18:00 Hrs [IST] ...

Algiax Pharmaceuticals, a clinical-stage biotech company focused on developing innovative treatments for chronic neuropathic pain, today announced compelling topline data from its Phase 2a clinical ...

Allosteric GABAA-receptor modulator AP-325 showed rapid onset as well as long-lasting pain reduction in patients with chronic neuropathic pain in Phase 2a study Data confirm previously reported ...

Brief pain inventory; LANSS: Leeds assessment of neuropathic symptoms and signs; MPQ: McGill pain questionnaire; NPS: Neuropathic pain scale; NRS: Numerical rating scale; VAS: Visual analog score.

Accurate pain reporting in sickle cell disease is critical to effective pain assessment and management, but accuracy depends on patient comprehension of forms.

The FDA approves Vertex's non-opioid oral pain signal inhibitor, Journavx, for treating adults with moderate-to-severe acute pain. Shares rise.

The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...

Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 ...

Audiencerate, a leader in data intelligence and AI solutions for digital marketing, is pleased to announce the appointment of Nicola Boschetti to the Board of Audiencerate Italy. Boschetti brings ...

Vertex is also evaluating suzetrigine in peripheral neuropathic pain (PNP). The company's Phase 3 pivotal program ... announced a strategic partnership to continue deploying large-scale installations ...

The Phase IIa results continue a surge of momentum in a treatment space that last week saw the approval of Vertex’s Journavx ...